Caplin Point Laboratories Ltd Share Price (CAPLIPOINT)

Caplin Point Subsidiary Receives FDA Approval - 16 Apr, 2024

Caplin Point Laboratories' subsidiary, Caplin Steriles, has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ofloxacin Ophthalmic Solution. The solution is used to treat eye infections caused by conjunctivitis and corneal ulcers.

Insiders Receive 70% Cut as Caplin Point Laboratories Market Cap Increases - 02 Apr, 2024

Caplin Point Laboratories' market cap has increased by ₹7.8b, with insiders receiving a 70% cut. The company's significant insider control implies vested interests in growth, with three investors holding a majority stake of 55%. Ownership research can provide insight into opportunities for the stock.

Caplin Steriles Receives FDA Approval for Generic Eye Drops - 28 Mar, 2024

Caplin Point Laboratories' subsidiary, Caplin Steriles Ltd, has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) Ketorolac tromethamine ophthalmic solution 0.5% (eye drops), causing a 2.78% increase in shares.

Caplin Point Labs Completes Oncology Facility, Plans to Expand Portfolio - 27 Mar, 2024

Caplin Point Laboratories' subsidiary, Caplin One Labs, has completed its oncology facility in Chennai and plans to expand the portfolio to over 50 products. The facility will manufacture tablets, capsules, and injections for Latin American countries initially, with plans to launch in regulated markets such as the US and EU in the medium term. The company's Q3 FY24 net profit jumped 30.1% YoY to Rs 119.82 crore on a 17% increase in revenue from operations.